Aravive Inc.

11/12/2019 | Press release | Distributed by Public on 11/12/2019 07:04

Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial[...]